DISCOUNT-ZERTIFIKAT - NOVARTIS N Stock

Certificat

DE000SU0DW87

Market Closed - Deutsche Boerse AG 03:38:10 2024-05-24 pm EDT
73.74 EUR -0.46% Intraday chart for DISCOUNT-ZERTIFIKAT - NOVARTIS N
Current month-0.45%
1 month-0.73%
Date Price Change
24-05-24 73.74 -0.46%
24-05-23 74.08 +0.11%
24-05-22 74 -0.20%
24-05-21 74.15 -0.01%
24-05-20 74.16 -0.05%

Delayed Quote Deutsche Boerse AG

Last update May 24, 2024 at 03:38 pm EDT

More quotes

Static data

Product typeCertificats Discount
Buy / SellCALL
Underlying NOVARTIS AG
IssuerLogo Issuer Société Générale Société Générale
WKN SU0DW8
ISINDE000SU0DW87
Date issued 2023-10-06
Cap 75 CHF
Last trading day 2025-03-20
Maturity 2025-03-21 (299 Days)
Parity 1 : 1
Emission price 72.04
Emission volume N/A
Payment day 2025-03-28
Bonus-
Settlement les deux
Currency EUR

Technical Indicators

Discount (ask) 0.000000 %
Sideways yield 0.000000 %
Sideways yield pa 0.000000 %
Outperformance point- CHF
Break even 0.000000 €
Highest since issue 77.43
Lowest since issue 71.59
Distance Cap 16.74 CHF
Distance Cap %+18.25%
Max. earning-
Max. earning % 0.000000 %

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
-
More about the company

Ratings for Novartis AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Novartis AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
100.4 USD
Average target price
108 USD
Spread / Average Target
+7.64%
Consensus